Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | Comparing CEM and MRI for assessing treatment responses in breast cancer

Carolina Sobrido, MD, PhD, Clínica Universidad de Navarra, Madrid, Spain, discusses the role of imaging techniques, such as contrast-enhanced mammography (CEM) and MRI, in assessing residual disease in patients with breast cancer after neoadjuvant treatment. Both techniques have their advantages, with CEM being faster and more accessible, while MRI provides a more complex assessment of extensive or complex disease. Imaging plays a crucial role in predicting pathological complete response and surgical planning. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Both techniques provide functional information, and both can help us assess residual disease. However, contrast-enhanced mammography, or CEM, is a very promising alternative. CEM is faster, more accessible, and often better tolerated by patients. However, MRI provides a more complex assessment, particularly when we need to evaluate extensive or complex disease. It provides excellent information about residual disease, tumor extent, multifocality, and also the axilla...

Both techniques provide functional information, and both can help us assess residual disease. However, contrast-enhanced mammography, or CEM, is a very promising alternative. CEM is faster, more accessible, and often better tolerated by patients. However, MRI provides a more complex assessment, particularly when we need to evaluate extensive or complex disease. It provides excellent information about residual disease, tumor extent, multifocality, and also the axilla. We should not ask which technique wins. We should ask which technique best answers the question for the patient in front of us. Imaging plays a very important role in predicting pathological complete response after neoadjuvant treatment. Studies have shown good diagnostic accuracy. For example, a large meta-analysis of breast MRI reporting an area under the curve of 0.88 for detecting residual disease. However, a complete imaging response does not always mean pathological complete response. Even when there is no residual enhancement, small areas of residual disease may still be present. The accuracy of imaging also depends on the molecular subtype with better results in HER2 positive and triple negative breast cancers. Imaging plays an important role in surgical planning. It helps us select patients for breast-conserving surgery. However, at present, imaging alone is not accurate enough to safely omit surgery. This is an important area of ongoing research. And in the future, selected patients with a complete imaging response may be able to avoid surgery. But today, surgical de-escalation means reducing the extent of surgery, not eliminating it.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.